|
Therapeutic efficacy of pegasys in 4 patients with chronic hepatitis B |
||||
| Characteristics |
Case 1 |
Case 2 |
Case 3 |
Case 4 |
|
|
||||
| Sex |
Female |
Male |
Male |
Male |
| Age(yr) |
14 |
24 |
39 |
49 |
| Course of diseasea(yr) |
3 |
2 |
1 |
1 |
| Therapy |
Monotherapy |
Monotherapy |
Sequential therapy |
Sequential therapy |
| Course of treatmentb(wk) |
36 |
40 |
24 |
44 |
| HBV DNA undetectablec |
Week 14 |
Week 16 |
Week 20 |
Week 14 |
| ALT normalization |
Week 36 |
Week 26 |
Week 23 |
Week 14 |
| HBeAg seroconversion |
Week 16 |
Week 22 |
Week 23 |
Week 38 |
| HBsAg clearance |
Week 17 |
Week 40 |
Week 24 |
Week 44 |
| HBsAg seroconversion |
Week 20 |
-- |
-- |
-- |
|
yr, year; wk, week; ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus. a interval between the first time when HBsAg-positive was detected and the date before treatment. b cumulate course between the first day of anti-HBV treatment and the date when complete response occurred. c HBV DNA<1000 copies/ml. | ||||
Yang and Zhao Virology Journal 2009 6:97 doi:10.1186/1743-422X-6-97 |
||||